First-Line Therapy With Bispecific Antibody for EGFR-Mutated NSCLC

Supportive Care Reduces AEs With MARIPOSA Regimen in EGFR+ NSCLC

During a live event, Shirish M. Gadgeel, MD, discussed different management approaches to the improve tolerability of amivantamab/lazertinib in EGFR-mutated lung cancer.

Polling Data Show Updates in Treatment of mNSCLC With EGFR Mutations

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

Polling Data Show Updates in Treatment of mNSCLC With EGFR Mutations

Oncologists share their treatment preferences for patients with advanced NSCLC with EGFR mutations.

Studies Find Supportive Care Approaches for Amivantamab in Lung Cancer

During a live event, Xiuning Le, MD, PhD, discussed clinical trials of supportive care for infusion reaction and skin rash with amivantamab in EGFR-mutated lung cancer.

Amivantamab/Lazertinib Shows OS and PFS Benefits in EGFR-Mutated NSCLC

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Discussing Lung Cancer NGS Testing and EGFR Treatment Strategies

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their approaches.

Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.

MARIPOSA Trial Shows PFS Benefit With or Without CNS Disease in NSCLC

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small cell lung cancer in the first article of a 2-part series.

Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment

During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.

Selection of First-Line NSCLC Therapy Influenced by Delayed Testing

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, asked participants how they would approach therapy for a patient with metastatic non–small cell lung cancer when biomarker testing is not yet completed. This is the second of 2 articles based on this event.

Comprehensive Molecular Testing Needed for Frontline NSCLC Treatment

During a Targeted Oncology™ Case-Based Roundtable™ event, Misako Nagasaka, MD, PhD, held a discussion on the use of biomarker testing in patients with advanced non–small cell lung cancer. This is the first of 2 articles based on this event.

Discussing Response of Amivantamab in EGFR Exon 20+ NSCLC

In the second article of a 2-part series, Martin F. Dietrich, MD, PhD, discusses the results of the phase 1 CHRYSALIS study of amivantamab for patients with EGFR exon 20 insertion-mutated NSCLC.

Amivantamab Provides New Treatment Approach in EGFR Exon 20+ NSCLC

In the first article of a 2-part series, Martin F. Dietrich, MD, PhD, discusses what makes amivantamab a promising treatment for patients with EGFR Exon 20 mutated non–small cell lung cancer.

Areas of Concern in Using Amivantamab and Mobocertinib in EGFR Exon 20+ NSCLC

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed with participants how they would use the FDA-approved therapies amivantamab and mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion alteration. This is the second of 2 articles based on this event.

Amivantamab Compared With Real-World EGFR Exon 20 NSCLC Population

During a Targeted Oncology™ Case-Based Roundtable™ event, Joshua K. Sabari, MD, discussed research supporting the use of amivantamab for patients with non–small cell lung cancer and an EGFR exon 20 insertion, including data comparing with real-world cohorts of similar patients treated with other agents.

Amivantamab Shows Strong Efficacy in NSCLC With EGFR Exon 20 Insertion

Erminia Massarelli, MD, PhD, MS, discusses the efficacy outcomes of the CHRYSALIS trial of amivantamab in patients with non–small cell lung cancer and an EGFR exon 20 insertion.

Results of Amivantamab and Mobocertinib Trials Evaluated for Use in NSCLC

During a Targeted Oncology case-based roundtable event, Christine Bestvina, MD, discussed the outcomes of clinical trials of the EGFR exon 20-targeted agents amivantamab and mobocertinib with participants. This is the second of 2 articles based on this event.

Identifying Second-Line Options for NSCLC With EGFR Exon 20 Insertions

During a live virtual event, Christine Bestvina, MD, discussed the use of amivantamab and mobocertinib, 2 new targeted therapies for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

EGFR Therapies Fail to Benefit Patients With NSCLC and Exon 20 Insertions

Joshua K. Sabari, MD, discusses the significance of EGFR exon 20 insertion mutations in patients with non–small cell lung cancer.

Tsao Picks Second-Line Therapy for a Patient With EGFR Exon 20+ NSCLC

During a live virtual event, Anne S. Tsao, MD, discussed the choice of targeted therapy for a patient with non–small cell lung cancer with an EGFR exon 20 insertion.

Using and Sequencing EGFR Exon 20-Targeted Therapies for NSCLC

Xiuning Le, MD, PhD, discusses counseling patients on the use of amivantamab-vmjw and mobocertinib and the sequencing of these drugs for patients with non–small cell lung cancer and an EGFR exon 20 insertion.